Sanuwave Health (OTC:SNWV) said today it tapped Lithomed as its orthopedic product distributor in Taiwan.
Suwanee, Ga.-based Sanuwave said the selection of Lithomed was the result of an extensive search in the region, and that the contract comes with a minimum order value of $500,000.
“Sanuwave has committed to deliver 3-5 new distribution partners in the second quarter and 7-10 by the end of the year. This is the first step in achieving or beating our target. We are also excited to be able to support our science advisor Dr. Chin-Jen Wang, Professor of Orthopedic Surgery at Chang Gung Memorial Hospital, and his newly founded Shockwave Institute in Bang Dong, Taiwan,” CEO & chair Kevin Richardson II said in a prepared statement.
“Lithomed is very pleased to be the distributor for Sanuwave’s orthopedic products in Taiwan. The orthoPACE® device, with its patented focused shock wave technology, is an important advancement in orthopedic and musculoskeletal care and offers a wide range of non-invasive treatment procedures for hospitals and doctor’s offices. I am certain it will be welcomed by Taiwanese orthopedists and their patients. These innovative products will fit perfectly within our portfolio and will be a welcomed addition to our current network of loyal customers and users. The orthoPACE device has been proven safe and effective for the treatment of chronic tendonitis and joint pain in the musculoskeletal environment. orthoPACE treatments have been especially effective in treating tendonitis and plantar fasciitis, which commonly require surgery. orthoPACE is designed to effectively treat bone conditions requiring osteogenesis, calcific joints, conditions causing painful joints, and chronic pain caused by musculoskeletal disorders. orthoPACE uses focused, shock wave treatments that are non-invasive which dramatically reduce the risk of infection. In many indications, orthoPACE has a proven success rate that is equal to or greater than that of surgery — usually with just one procedure and without the inherent risks, complications, or lengthy recovery time of invasive surgery. orthoPACE treatments require a minimal amount of treatment time. In conditions such as plantar fasciitis, patients can bear weight immediately and return to pre-treatment activity within a few days of the procedure,” Lithomed managing director William Kao said in a press release.
Last August, Sanuwave Health said it filed a de novo petition with the FDA as it seeks approval for its DermaPace system designed for treating diabetic foot ulcers.
